



PATIENT REPORT

PATIENT

Patient name:

Sample ID: 0000000

Date of birth:

ORDER

Specimen collected:

Date of report:

Ordering physician:

Clinic/hospital:



TEST RESULTS

TNF α Inhibitor

*Tumor Necrosis Factor
Alpha Inhibitor*

IL-17 Inhibitor

Interleukin 17 Inhibitor

IL-23 Inhibitor

Interleukin 23 Inhibitor

ABOUT MIND.PX/METHODOLOGY

Mind.Px™ is a transcriptome analysis test combined with proprietary Mindera Health Dermal Biomarker Patch (DBP), to provide insights on immune-related pathways involved in the pathogenesis of psoriasis. Psoriasis pathogenesis involves a complex interplay between IL-17, IL-23, and other cytokines that play crucial roles as key regulators of the chronic inflammatory condition. By deciphering the immune pathway in an individual psoriasis lesion, Mind.Px provides a preferred disease immunopathologic pathway to support disease treatment management.

mRNA is extracted from a psoriatic lesion using the DBP, and from the submitted sample, whole transcriptome data are generated using an Illumina Sequencing Platform.

The Mind.Px score stratifies an individual by current immune-related pathway associated with psoriasis pathogenicity. The positive predictive value (PPV) of Mind.Px is >91%, where a positive result is defined as a patient having a minimum of a PASI75 response at 12-16 weeks after dosing.

Example Signature

If you have any questions about Mind.Px or how to use the Mind.Px test result, please contact Mindera Health clinical support at Mind.Px@minderahaalth.com or 858-810-6070

DISCLAIMER


Mind.Px is not designed to independently diagnose, prevent, or treat any condition of disease, or to ascertain the state of an individual's health in the absence of medical or clinical information. An individual should consult healthcare provider to make medical decision, change their health behavior or make changes to medications or dosage.

The test is intended for use as an aid for clinicians and patients considering the risks and benefits of psoriasis management and treatments.

This test was performed by Mindera Health, 1221 Liberty Way, Vista, CA 92081. Mindera Health is a CLIA-certified CAP-Accredited, and HIPAA compliant laboratory (CLIA #: 05D2189599, CAP #: 8813410). This test has not been cleared or approved by the US Food and Drug Administration.



Predict Patient Response to Psoriasis Biologics



AAD guidelines state, “There is... an important need to identify biomarkers that can potentially predict the appropriate biologic agent for individual patients.”¹

It’s widely understood that a test predicting psoriasis treatment response to a class of biologic drugs would lessen trial and error. In a recent survey of community dermatologists², there was overwhelming agreement that such a test would:

- Enable more informed decisions about drug selection
- Improve patient outcomes
- Significantly reduce wasted spending

Introducing **Mind.Px**, a patient transcriptome from Mindera Health that correlates RNA to drug response for psoriatic biologics. Mind.Px offers you a(n):

- Painless, minimally invasive test
- Patch applied remotely to avoid office disruption
- Patch placed on skin for 5 minutes
- Over 7,000 biomarkers per test sample
- Predicts biologic drug response to better select the ideal therapy



Please scan for more information.

References

1. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with Biologics. *JAAD*. Volume 80, Issue 4, P1029-1072, April 01, 2019.
2. Strober, B., Pariser, D., Deren-Lewis, A. et al. A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm. *Dermatol Ther* (Heidelb) (2021).

THE MIND.PX WORKFLOW



APPLY



EXTRACT



SEQUENCE & ANALYZE



Mindera Laboratory is a HIPAA compliant, CLIA-certified, and CAP-accredited laboratory (CLIA #05D2189599, CAP #8813410).

minderahhealth.com

1221 Liberty Way, Vista, CA 92081 | Tel: (858) 810-6070

© Copyright 2025 Mindera Health | ISO 13485:2016 certified

MAR00783.C